注册和未注册的骨髓增生异常综合征患者的诊断检测、治疗、护理费用和生存情况。
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.
机构信息
Health Outcomes & Behavior, H. Lee Moffitt Cancer Center & Research Institute, MRC-CANCONT, Tampa, FL 33612-9416, USA.
出版信息
Leuk Res. 2011 Nov;35(11):1453-6. doi: 10.1016/j.leukres.2011.07.028. Epub 2011 Aug 17.
Abstract
Considering current reliance on cancer registry data, we sought to assess the potential for bias in myelodysplastic syndrome (MDS) registration using SEER-Medicare data 2001-2005. Using a validated claims-based algorithm, we identified and compared registered and non-registered MDS patients, and found that median cumulative survival was 18 and 28 months, 74% and 64% used erythropoiesis-stimulating agents (ESAs), and average 6-month health care cost was $24,249 and $21,750, respectively. While most non-registered MDS patients showed resource utilization and survival characteristics consistent with lower-risk MDS, a subset was registered as acute myeloid leukemia (7.6%) and accounted for early mortality.
摘要
考虑到目前对癌症登记数据的依赖，我们试图利用 SEER-Medicare 数据（2001-2005 年）评估骨髓增生异常综合征（MDS）登记中存在的偏倚的可能性。我们使用经过验证的基于索赔的算法，确定并比较了登记和未登记的 MDS 患者，发现中位累积生存率分别为 18 个月和 28 个月，74%和 64%使用红细胞生成刺激剂（ESA），平均 6 个月的医疗保健费用分别为 24249 美元和 21750 美元。虽然大多数未登记的 MDS 患者的资源利用和生存特征与低危 MDS 一致，但有一部分被登记为急性髓系白血病（7.6%），并导致早期死亡。
相似文献
1
Diagnostic testing, treatment, cost of care, and survival among registered and non-registered patients with myelodysplastic syndromes.注册和未注册的骨髓增生异常综合征患者的诊断检测、治疗、护理费用和生存情况。
Leuk Res. 2011 Nov;35(11):1453-6. doi: 10.1016/j.leukres.2011.07.028. Epub 2011 Aug 17.
2
Disease-related costs of care and survival among Medicare-enrolled patients with myelodysplastic syndromes.参加医疗保险的骨髓增生异常综合征患者的疾病相关护理费用及生存情况
Cancer. 2016 May 15;122(10):1598-607. doi: 10.1002/cncr.29945. Epub 2016 Mar 11.
3
Healthcare resource utilization and costs in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis.接受低甲基化药物治疗的骨髓增生异常综合征患者的医疗资源利用和成本：一项 SEER-医疗保险分析。
J Med Econ. 2021 Jan-Dec;24(1):234-243. doi: 10.1080/13696998.2021.1876714.
4
Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.强化诱导或挽救化疗后急性髓系白血病或骨髓增生异常综合征门诊管理的资源利用和安全性：一项非随机临床对比分析。
JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.
5
Patterns of erythropoiesis-stimulating agent use among Medicare beneficiaries with myelodysplastic syndromes and consistency with clinical guidelines.医保受益人群中骨髓增生异常综合征患者促红细胞生成素刺激剂的使用模式及其与临床指南的一致性。
Leuk Res. 2013 Jun;37(6):675-80. doi: 10.1016/j.leukres.2013.02.021. Epub 2013 Mar 21.
6
Patient cost sharing and receipt of erythropoiesis-stimulating agents through medicare part D.患者成本分担以及通过医疗保险D部分获得促红细胞生成素
J Oncol Pract. 2015 Mar;11(2):e190-8. doi: 10.1200/JOP.2014.001527. Epub 2015 Jan 6.
7
Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.从美国支付者角度评估地西他滨与最佳支持治疗中高危骨髓增生异常综合征的经济学分析。
Clin Ther. 2010 Dec;32(14):2444-56. doi: 10.1016/j.clinthera.2010.12.003.
8
Healthcare resource utilization of patients with lower-risk myelodysplastic syndromes treated with luspatercept versus erythropoiesis-stimulating agents: a United States healthcare claims database study.与促红细胞生成剂相比，接受鲁索替尼治疗的低危骨髓增生异常综合征患者的医疗资源利用情况：一项美国医疗保健索赔数据库研究
J Med Econ. 2025 Dec;28(1):719-725. doi: 10.1080/13696998.2025.2498852. Epub 2025 May 21.
9
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.阿扎胞苷治疗骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓系白血病。
Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10.
10
Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.骨髓增生异常综合征的诊断与治疗：综述
JAMA. 2022 Sep 6;328(9):872-880. doi: 10.1001/jama.2022.14578.
引用本文的文献
1
Burden of myelodysplastic syndromes: a systematic literature review of economic burden.骨髓增生异常综合征的负担：经济负担的系统文献综述
Eur J Health Econ. 2025 Apr 23. doi: 10.1007/s10198-025-01779-2.
2
Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.强化诱导或挽救化疗后急性髓系白血病或骨髓增生异常综合征门诊管理的资源利用和安全性：一项非随机临床对比分析。
JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.
3
Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.1973 - 2011年美国骨髓增殖性肿瘤发病率的变化：趋势及亚组风险概况
J Cancer Res Clin Oncol. 2015 Dec;141(12):2131-8. doi: 10.1007/s00432-015-1983-5. Epub 2015 May 13.
4
Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects.癌症基因组学和精准医学中的比较疗效研究：现状与未来展望。
J Natl Cancer Inst. 2013 Jul 3;105(13):929-36. doi: 10.1093/jnci/djt108. Epub 2013 May 9.
5
Treatment and outcomes for chronic myelomonocytic leukemia compared to myelodysplastic syndromes in older adults.老年人群慢性髓单核细胞白血病与骨髓增生异常综合征的治疗和结局比较。
Haematologica. 2013 Apr;98(4):584-90. doi: 10.3324/haematol.2012.062547. Epub 2012 Nov 9.
6
The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes.低甲基化剂对老年骨髓增生异常综合征患者的治疗费用和生存的影响。
Leuk Res. 2012 Nov;36(11):1370-5. doi: 10.1016/j.leukres.2012.07.020. Epub 2012 Aug 20.
7
Underreporting of myeloid malignancies by United States cancer registries.美国癌症登记处对髓系恶性肿瘤的漏报。
Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):474-81. doi: 10.1158/1055-9965.EPI-11-1087. Epub 2012 Jan 11.
本文引用的文献
1
Incidence and prevalence of myelodysplastic syndromes: data from the Düsseldorf MDS-registry.骨髓增生异常综合征的发病率和患病率：杜塞尔多夫 MDS 登记处的数据。
Leuk Res. 2011 Dec;35(12):1591-6. doi: 10.1016/j.leukres.2011.06.001. Epub 2011 Jun 25.
2
Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries.采用新型基于索赔的算法评估骨髓增生异常综合征的发病情况：癌症登记处漏报大量病例。
Blood. 2011 Jun 30;117(26):7121-5. doi: 10.1182/blood-2011-02-337964. Epub 2011 Apr 29.
3
Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project.欧洲形态亚型血液系统恶性肿瘤的发病率：HAEMACARE 项目的结果。
Blood. 2010 Nov 11;116(19):3724-34. doi: 10.1182/blood-2010-05-282632. Epub 2010 Jul 27.
4
Incidence and clinical complications of myelodysplastic syndromes among United States Medicare beneficiaries.美国医疗保险受益人群中骨髓增生异常综合征的发病率及临床并发症。
J Clin Oncol. 2010 Jun 10;28(17):2847-52. doi: 10.1200/JCO.2009.25.2395. Epub 2010 Apr 26.
5
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.利用北美癌症登记协会（NAACCR）和监测、流行病学与最终结果（SEER）项目的数据，对2001 - 2004年美国骨髓增生异常综合征和慢性骨髓增殖性疾病的流行病学进行研究。
Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28.
6
Myelodysplastic syndromes: incidence and survival in the United States.骨髓增生异常综合征：美国的发病率与生存率
Cancer. 2007 Apr 15;109(8):1536-42. doi: 10.1002/cncr.22570.
7
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.来那度胺治疗伴有5号染色体长臂缺失的骨髓增生异常综合征
N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292.
8
Efficacy of lenalidomide in myelodysplastic syndromes.来那度胺在骨髓增生异常综合征中的疗效。
N Engl J Med. 2005 Feb 10;352(6):549-57. doi: 10.1056/NEJMoa041668.
9
Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population.SEER-医疗保险数据概述：内容、研究应用及对美国老年人群的普遍性
Med Care. 2002 Aug;40(8 Suppl):IV-3-18. doi: 10.1097/01.MLR.0000020942.47004.03.
10
International scoring system for evaluating prognosis in myelodysplastic syndromes.评估骨髓增生异常综合征预后的国际评分系统。
Blood. 1997 Mar 15;89(6):2079-88.
Zotero 插件